Hadassah Medical Center

Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center

Retrieved on: 
Wednesday, May 24, 2023
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Partnership, Al-Quds, Hebrew University of Jerusalem, Technology transfer, Quinone, Nidaa Khoury, Bacteriophage, Infection, Phage therapy, Multimedia, Staphylococcus, Doctor of Philosophy, Staphylococcus aureus, Acinetobacter baumannii, Pseudomonas aeruginosa, Hospital, Rimon School of Jazz and Contemporary Music, IPTC, Biomedicine, Patient, PubMed, Hadassah Medical Center, APT, Bacteria, European Society of Clinical Microbiology and Infectious Diseases, Medicine, Pharmaceutical industry, MD

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center.

Key Points: 
  • Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center.
  • APT also has the first right to evaluate additional phages discovered by IPTC researchers for inclusion in APT’s phage bank.
  • “We are thrilled to enter into this collaboration and license agreement and to continue our work with Dr. Nir-Paz, Dr. Hazan, and the impressive group of phage scientists at Hebrew University and Hadassah Medical Center.
  • I am thrilled to see the Israeli Phage Therapy Center entering into a collaboration and licensing agreement with Adaptive Phage Therapeutics, the leading phage therapy biotech firm,” said Ran Nir-Paz, MD, Professor of Clinical Microbiology and Medicine at the department of Clinical Microbiology and Infectious Diseases at the Hadassah Hebrew University Medical Center and co-founder of the Israeli Phage Therapy Center.

Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

Retrieved on: 
Sunday, May 21, 2023
Hematopoietic stem cell transplantation, Gene, CRS, AL amyloidosis, MRD, Hadassah Medical Center, Clinical trial, AL, Patient, Amyloidosis, Cell, LOS, Daratumumab, Society, BCMA, Immunotherapy

Additional NXC-201 clinical data was presented on eight DARZALEX® (daratumumab) relapsed or refractory AL amyloidosis patients.

Key Points: 
  • Additional NXC-201 clinical data was presented on eight DARZALEX® (daratumumab) relapsed or refractory AL amyloidosis patients.
  • The new data are being presented during a late-breaking oral presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) in Los Angeles on May 19, 2023.
  • “In AL amyloidosis, these data are compelling as recent trials demonstrate an overall response rate of 55% for DARZALEX-relapsed or refractory AL amyloidosis patients receiving investigator’s choice.
  • Importantly, NXC-201 may offer a valuable option for the increasing number of AL amyloidosis patients who have progressed on DARZALEX-based standards of care.”
    Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

Retrieved on: 
Sunday, May 21, 2023
Hematopoietic stem cell transplantation, Gene, CRS, AL amyloidosis, MRD, Hadassah Medical Center, Clinical trial, AL, Patient, Amyloidosis, Cell, LOS, Daratumumab, Society, BCMA, Dentistry, Immunotherapy

Additional NXC-201 clinical data was presented on eight DARZALEX ® (daratumumab) relapsed or refractory AL amyloidosis patients.

Key Points: 
  • Additional NXC-201 clinical data was presented on eight DARZALEX ® (daratumumab) relapsed or refractory AL amyloidosis patients.
  • The new data are being presented during a late-breaking oral presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) in Los Angeles on May 19, 2023.
  • “In AL amyloidosis, these data are compelling as recent trials demonstrate an overall response rate of 55% for DARZALEX-relapsed or refractory AL amyloidosis patients receiving investigator’s choice.
  • Importantly, NXC-201 may offer a valuable option for the increasing number of AL amyloidosis patients who have progressed on DARZALEX-based standards of care.”
    Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

Nexcella Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

Retrieved on: 
Thursday, May 4, 2023
Hematopoietic stem cell transplantation, Gene, Cell therapy, AL amyloidosis, Hadassah Medical Center, Amyloidosis, Cell, Society, Immunotherapy

LOS ANGELES, May 04, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (Nasdaq: IMMX) (“Nexcella”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Los Angeles May 16-20, 2023.

Key Points: 
  • LOS ANGELES, May 04, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (Nasdaq: IMMX) (“Nexcella”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Los Angeles May 16-20, 2023.
  • “We are delighted to present additional clinical data for what we believe is the only CAR-T in development in AL Amyloidosis at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator for the NEXICART-1 Phase 1b/2a clinical trial of NXC-201.
  • “A potential one-time treatment such as CAR-T NXC-201 in AL amyloidosis would be a welcome option for this devastating disease.”
    Event: 26th Annual Meeting of The American Society of Gene and Cell Therapy, Los Angeles, CA

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

Retrieved on: 
Thursday, May 4, 2023
Hematopoietic stem cell transplantation, Gene, Cell therapy, AL amyloidosis, Hadassah Medical Center, Amyloidosis, Cell, Society, Immunotherapy

LOS ANGELES, May 04, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Los Angeles May 16-20, 2023.

Key Points: 
  • LOS ANGELES, May 04, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) to be held in Los Angeles May 16-20, 2023.
  • “We are delighted to present additional clinical data for what we believe is the only CAR-T in development in AL Amyloidosis at the upcoming 26th Annual Meeting of The American Society of Gene & Cell Therapy,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator for the NEXICART-1 Phase 1b/2a clinical trial of NXC-201.
  • “A potential one-time treatment such as CAR-T NXC-201 in AL amyloidosis would be a welcome option for this devastating disease.”
    Event: 26th Annual Meeting of The American Society of Gene and Cell Therapy, Los Angeles, CA

EXOSOMM Looks to the Benefits of Mother's Milk to Bring New Bioactive Ingredient for Medical Food Space

Retrieved on: 
Wednesday, May 3, 2023
Nanoparticle, Obesity, Food, Diabetes, IBD, Israeli cuisine, Infection, 3D, Mammal, Food safety, Exosome, Inflammatory bowel disease, Quality of life, MicroRNA, Cheese, Research, Inflammation, RNA, DSM-IV codes, Virtue, Crohn's disease, Milk, Sheep, Patient, Child, Immune system, Hadassah Medical Center, Growth, IMI Galil, Health, University Medical Center Schleswig Holstein, Vaccine, Dairy, Dietary supplement, MD, Colitis

JERUSALEM, May 3, 2023 /PRNewswire/ -- BioFoodTech start-up EXOSOMM, Ltd., has explored the natural mechanisms inherent in human breastmilk to create a novel bioactive ingredient that can potentially support millions of adults with inflammatory disorders. Based on its scientific findings EXOSOMM developed an innovative technology that isolates exosomes—natural particles in maternal milk that play an important role in the healthy development of the immune system.

Key Points: 
  • EXOSOMM upcycles byproducts of the traditional cheese making process to create this potent functional ingredient.
  • While still a young start-up, it has already reached commercial production capacity of its patent-protected exosomes for the medical food space.
  • Moreover, it was important for us to derive the milk benefits without exerting any burden on milk production.
  • EXOSOMM has been selected as a finalist in the Most Innovative Nutraceutical Ingredient category at the upcoming Vitafoods Startup Innovation Challenge 2023.

Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris

Retrieved on: 
Wednesday, April 26, 2023
EBMT, Haematologica, Hematopoietic stem cell transplantation, Blood, Hospital, Multiple myeloma, AL amyloidosis, Clinical Cancer Research, Hope, Clinical data management system, Hadassah Medical Center, February 9–11, 2017 North American blizzard, Patient, Data, European, CEST, Paper, Liver, LOS, European Society for Medical Oncology, FDA, Safety, IND, BLA, CART, BCMA, Pharmaceutical industry, Semiconductor, Agrochemical, Vaccine, Nursing, Immunotherapy, Amyloidosis

The dataset represents 8 new evaluable patients in multiple myeloma and 3 new evaluable patients in light chain (AL) amyloidosis (paper and poster publications www.nexcella.com/publications ).

Key Points: 
  • The dataset represents 8 new evaluable patients in multiple myeloma and 3 new evaluable patients in light chain (AL) amyloidosis (paper and poster publications www.nexcella.com/publications ).
  • The new data are being presented during a poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting in Paris, France, April 23-26.
  • “In multiple myeloma, these data are compelling as the overall response rate for ABECMA was 72% in its pivotal KarMMa trial with 100 patients in relapsed or refractory multiple myeloma.
  • Nexcella plans to submit data to the FDA in AL amyloidosis once 30-40 patients are treated with NXC-201.

Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris

Retrieved on: 
Wednesday, April 26, 2023
EBMT, Haematologica, Hematopoietic stem cell transplantation, Blood, Hospital, Multiple myeloma, AL amyloidosis, Clinical Cancer Research, Hope, Clinical data management system, Hadassah Medical Center, February 9–11, 2017 North American blizzard, Patient, Data, European, CEST, Paper, LOS, Liver, European Society for Medical Oncology, FDA, Safety, IND, BLA, CART, BCMA, Pharmaceutical industry, Semiconductor, Agrochemical, Vaccine, Nursing, Immunotherapy, Amyloidosis

The dataset represents 8 new evaluable patients in multiple myeloma and 3 new evaluable patients in light chain (AL) amyloidosis (paper and poster publications www.nexcella.com/publications ).

Key Points: 
  • The dataset represents 8 new evaluable patients in multiple myeloma and 3 new evaluable patients in light chain (AL) amyloidosis (paper and poster publications www.nexcella.com/publications ).
  • The new data are being presented during a poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting in Paris, France, April 23-26.
  • “In multiple myeloma, these data are compelling as the overall response rate for ABECMA was 72% in its pivotal KarMMa trial with 100 patients in relapsed or refractory multiple myeloma.
  • Nexcella plans to submit data to the FDA in AL amyloidosis once 30-40 patients are treated with NXC-201.

RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Retrieved on: 
Wednesday, April 26, 2023
Research, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Optical, Science, Other Science, Maintenance, ARVO, FAF, Retinal, AMD, University Medical Center, Eye, Geographic atrophy, Quality of life, Hadassah Medical Center, GA, Trial of the century, Iris (anatomy), Patient, TASE, OCT, ELM, NYSE American, Lineage Cell Therapeutics, RPE, Letter, Therapy, Visual acuity, Atrophy, Disease, Medical imaging, Fine chemical, Pharmaceutical industry, Telescopic sight, Cosmetics, Nursing, Lineage, Genentech, Ophthalmology

RG6501 (OpRegen) is an allogeneic retinal pigment epithelial (RPE) cell therapy currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Key Points: 
  • RG6501 (OpRegen) is an allogeneic retinal pigment epithelial (RPE) cell therapy currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • Long term vision preservation with outer retinal structure improvement observed in the OpRegen treated eye persisted for up to 4 years of follow-up.
  • Further assessment of the optimal disease stage for intervention and target delivery location of OpRegen in a larger clinical study is needed to confirm these preliminary findings.
  • A Phase 2a study evaluating the success of OpRegen delivery to target areas of GA is currently enrolling patients (ClinicalTrials.gov: NCT05626114).

Nexcella announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting

Retrieved on: 
Tuesday, April 4, 2023
EBMT, Hematopoietic stem cell transplantation, Blood, CRS, Multiple myeloma, AL amyloidosis, Clinical trial, Clinical Cancer Research, Hadassah Medical Center, CAR, AL, Patient, CEST, Amyloidosis, Liver, European Society for Primary Immunodeficiencies, ORR, CART, BCMA, Pharmaceutical industry, Immunotherapy

LOS ANGELES, April 04, 2023 (GLOBE NEWSWIRE) -- Nexcella Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected to be presented at the upcoming 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held in Paris, France, 23-26 April 2023.

Key Points: 
  • LOS ANGELES, April 04, 2023 (GLOBE NEWSWIRE) -- Nexcella Inc. (“Nexcella”, “Company”, “We” or “Us”) today announced that updated NXC-201 clinical data has been selected to be presented at the upcoming 49th annual meeting of the European Society for Blood and Marrow Transplantation (EBMT) to be held in Paris, France, 23-26 April 2023.
  • “We are delighted to present additional clinical data at the upcoming 49th annual meeting of the European Society for Blood and Marrow Transplantation,” said Polina Stepensky, M.D., Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, and principal study investigator.
  • NXC-201 also produced 100% hematologic complete response rate and 100% organ response rate (cardiac, liver, renal) in 5 relapsed/refractory AL Amyloidosis patients as of the October 23, 2022 data cutoff.
  • These data were published in Haematologica https://doi.org/10.3324/haematol.2022.281628 (multiple myeloma), Clinical Cancer Research https://doi.org/10.1158/1078-0432.CCR-22-0637 (AL amyloidosis), and presented at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting https://www.nexcella.com/publications .